• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双膦酸盐肾病:病例系列及文献综述

Bisphosphonate nephropathy: A case series and review of the literature.

作者信息

de Roij van Zuijdewijn Camiel, van Dorp Wim, Florquin Sandrine, Roelofs Joris, Verburgh Kees

机构信息

Department of Internal Medicine, Spaarne Gasthuis, Haarlem/Hoofddorp, the Netherlands.

Department of Nephrology & Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

出版信息

Br J Clin Pharmacol. 2021 Sep;87(9):3485-3491. doi: 10.1111/bcp.14780. Epub 2021 Mar 4.

DOI:10.1111/bcp.14780
PMID:33595131
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8451932/
Abstract

From rat studies, human case reports and cohort studies, bisphosphonates seem to impair renal function. However, when critically reviewing the literature, zoledronate and pamidronate are more frequently involved in renal deterioration than other bisphosphonates. When bisphosphonate nephropathy occurs, zoledronate more frequently induces tubular toxicity whereas pamidronate typically induces focal segmental glomerulosclerosis. Thus, although bisphosphonates are highly effective in preventing complications for patients with osseous metastases and are highly effective in preventing fractures for patients with osteoporosis, renal function should be monitored closely after initiation of these drugs.

摘要

从大鼠研究、人类病例报告和队列研究来看,双膦酸盐似乎会损害肾功能。然而,在严格审视文献时,唑来膦酸和帕米膦酸比其他双膦酸盐更常导致肾功能恶化。当发生双膦酸盐肾病时,唑来膦酸更常诱发肾小管毒性,而帕米膦酸通常诱发局灶节段性肾小球硬化。因此,尽管双膦酸盐在预防骨转移患者的并发症方面非常有效,在预防骨质疏松症患者骨折方面也非常有效,但在开始使用这些药物后,应密切监测肾功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e34/8451932/19540e8abfcf/BCP-87-3485-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e34/8451932/11ab4c810b96/BCP-87-3485-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e34/8451932/550e859d7cee/BCP-87-3485-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e34/8451932/19540e8abfcf/BCP-87-3485-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e34/8451932/11ab4c810b96/BCP-87-3485-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e34/8451932/550e859d7cee/BCP-87-3485-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e34/8451932/19540e8abfcf/BCP-87-3485-g003.jpg

相似文献

1
Bisphosphonate nephropathy: A case series and review of the literature.双膦酸盐肾病:病例系列及文献综述
Br J Clin Pharmacol. 2021 Sep;87(9):3485-3491. doi: 10.1111/bcp.14780. Epub 2021 Mar 4.
2
Bisphosphonates in multiple myeloma: a network meta-analysis.双膦酸盐类药物治疗多发性骨髓瘤:一项网状Meta分析
Cochrane Database Syst Rev. 2012 May 16(5):CD003188. doi: 10.1002/14651858.CD003188.pub3.
3
Bisphosphonate nephrotoxicity.双膦酸盐类药物肾毒性
Kidney Int. 2008 Dec;74(11):1385-93. doi: 10.1038/ki.2008.356. Epub 2008 Aug 6.
4
[Bisphosphonate-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review].[双膦酸盐诱导的塌陷型局灶节段性肾小球硬化症;两例临床病例及文献综述]
Nephrol Ther. 2009 Apr;5(2):134-8. doi: 10.1016/j.nephro.2008.08.013. Epub 2008 Nov 13.
5
In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.双膦酸盐对人神经母细胞瘤细胞系的体外毒性
Anticancer Drugs. 2004 Sep;15(8):795-802. doi: 10.1097/00001813-200409000-00009.
6
An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.一项旨在确定在医院环境中,对被诊断为骨转移乳腺癌患者进行静脉注射双膦酸盐输注所需时间的审计。
Curr Med Res Opin. 2007 Jul;23(7):1575-82. doi: 10.1185/030079907x210543.
7
Bisphosphonates for breast cancer.用于乳腺癌的双膦酸盐类药物。
Cochrane Database Syst Rev. 2005 Jul 20(3):CD003474. doi: 10.1002/14651858.CD003474.pub2.
8
Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.双膦酸盐在成骨细胞和乳腺癌细胞之间的不同作用机制:一种强效新型双膦酸盐类似物的特性
Breast Cancer Res Treat. 2002 Feb;71(3):257-68. doi: 10.1023/a:1014418017382.
9
Toxic acute tubular necrosis following treatment with zoledronate (Zometa).唑来膦酸(择泰)治疗后出现的中毒性急性肾小管坏死。
Kidney Int. 2003 Jul;64(1):281-9. doi: 10.1046/j.1523-1755.2003.00071.x.
10
Ocular Side Effects of Bisphosphonates: A Review of Literature.双膦酸盐类药物的眼部副作用:文献综述
J Ocul Pharmacol Ther. 2023 Jan-Feb;39(1):3-16. doi: 10.1089/jop.2022.0094. Epub 2022 Nov 21.

引用本文的文献

1
Efficacy and safety of bisphosphonates in pediatric glucocorticoid-induced osteoporosis: a meta-analysis and pharmacovigilance study.双膦酸盐类药物治疗儿童糖皮质激素性骨质疏松症的疗效与安全性:一项荟萃分析及药物警戒研究
Front Pediatr. 2025 Jul 7;13:1571381. doi: 10.3389/fped.2025.1571381. eCollection 2025.
2
Single zoledronic acid infusion as a cause of acute kidney impairment requiring dialysis in two patients with osteoporosis.两例骨质疏松症患者单次唑来膦酸输注导致急性肾损伤需要透析。
Arch Endocrinol Metab. 2024 Nov 6;68:e240159. doi: 10.20945/2359-4292-2024-0159. eCollection 2024.
3
Update on kidney injury caused by multiple myeloma.

本文引用的文献

1
PubChem in 2021: new data content and improved web interfaces.PubChem 在 2021 年:新增数据内容和改进的网络界面。
Nucleic Acids Res. 2021 Jan 8;49(D1):D1388-D1395. doi: 10.1093/nar/gkaa971.
2
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets.2019/20 年简明药理学指南:引言和其他蛋白靶点。
Br J Pharmacol. 2019 Dec;176 Suppl 1(Suppl 1):S1-S20. doi: 10.1111/bph.14747.
3
Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States.
多发性骨髓瘤所致肾损伤的最新进展
Ann Hematol. 2024 Dec;103(12):5007-5018. doi: 10.1007/s00277-024-05860-3. Epub 2024 Jun 28.
4
Knowledge, attitude, and practice toward osteoporosis among patients with chronic kidney disease in Zhejiang.浙江省慢性肾脏病患者骨质疏松症的知识、态度和实践。
Medicine (Baltimore). 2024 May 17;103(20):e38153. doi: 10.1097/MD.0000000000038153.
5
Diagnosis and treatment of Paget's disease of bone: position paper from the Italian Society of Osteoporosis, Mineral Metabolism and Skeletal Diseases (SIOMMMS).骨 Paget 病的诊断和治疗:意大利骨质疏松症、矿物质代谢和骨骼疾病学会(SIOMMMS)立场文件。
J Endocrinol Invest. 2024 Jun;47(6):1335-1360. doi: 10.1007/s40618-024-02318-1. Epub 2024 Mar 15.
6
Bisphosphonates and Atypical Femur Fractures: Is the Relationship Causal or Casual?双膦酸盐与非典型股骨骨折:这种关系是因果关系还是偶然关系?
Cureus. 2023 Nov 2;15(11):e48141. doi: 10.7759/cureus.48141. eCollection 2023 Nov.
7
Melatonin induces RAW264.7 cell apoptosis via the BMAL1/ROS/MAPK-p38 pathway to improve postmenopausal osteoporosis.褪黑素通过BMAL1/ROS/MAPK-p38通路诱导RAW264.7细胞凋亡,以改善绝经后骨质疏松症。
Bone Joint Res. 2023 Nov 1;12(11):677-690. doi: 10.1302/2046-3758.1211.BJR-2022-0425.R3.
8
A Synopsis of Current Theories on Drug-Induced Nephrotoxicity.药物性肾毒性当前理论综述
Life (Basel). 2023 Jan 24;13(2):325. doi: 10.3390/life13020325.
9
The Role of Sympathetic Nerves in Osteoporosis: A Narrative Review.交感神经在骨质疏松症中的作用:一篇叙述性综述。
Biomedicines. 2022 Dec 23;11(1):33. doi: 10.3390/biomedicines11010033.
10
Exosomes derived from human umbilical cord mesenchymal stem cells promote osteogenesis through the AKT signaling pathway in postmenopausal osteoporosis.人脐带间充质干细胞来源的外泌体通过 AKT 信号通路促进绝经后骨质疏松症中的成骨作用。
Aging (Albany NY). 2022 Dec 27;14(24):10125-10136. doi: 10.18632/aging.204453.
美国临床实践中多发性骨髓瘤患者的肾功能损害及肾毒性药物的使用情况。
Cancer Med. 2017 Jul;6(7):1523-1530. doi: 10.1002/cam4.1075. Epub 2017 Jun 14.
4
Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study.单次静脉唑来膦酸给药对骨质疏松症患者急性肾损伤(AKI)生物标志物的影响:一项初步研究。
Br J Clin Pharmacol. 2017 Oct;83(10):2266-2273. doi: 10.1111/bcp.13332. Epub 2017 Jun 27.
5
Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials.利塞膦酸盐治疗轻度至中度慢性肾脏病合并骨质疏松症患者:利塞膦酸盐III期临床试验数据的事后分析
BMC Nephrol. 2017 Feb 15;18(1):66. doi: 10.1186/s12882-017-0478-9.
6
The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.绝经后女性骨质疏松症预防和治疗疗法的安全性和耐受性概况。
Expert Rev Clin Pharmacol. 2015;8(6):769-84. doi: 10.1586/17512433.2015.1099432. Epub 2015 Oct 20.
7
Nephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy.伊班膦酸盐和唑来膦酸在肾功能正常和单侧肾切除大鼠中的肾毒性。
Pharmacol Res. 2015 Sep;99:16-22. doi: 10.1016/j.phrs.2015.04.016. Epub 2015 May 11.
8
Treatment of osteoporosis in renal insufficiency.肾功能不全患者骨质疏松症的治疗
Clin Rheumatol. 2015 Aug;34(8):1341-5. doi: 10.1007/s10067-015-2883-4. Epub 2015 Jan 29.
9
Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project.癌症患者的急性肾损伤和双膦酸盐使用:来自不良药物事件和报告研究(RADAR)项目的报告。
J Oncol Pract. 2013 Mar;9(2):101-6. doi: 10.1200/JOP.2011.000486.
10
Oral bisphosphonate use in the elderly is not associated with acute kidney injury.老年人使用口服双膦酸盐与急性肾损伤无关。
Kidney Int. 2012 Oct;82(8):903-8. doi: 10.1038/ki.2012.227. Epub 2012 Jun 13.